- In March 2023, ICU Medical, Inc. acquired Rusoma Laboratories Pvt. Ltd. — an Indian manufacturer of non‑PVC IV bags — for USD 100 million. This strategic move expands ICU Medical’s footprint in Asia and significantly enhances its product portfolio in the global non‑PVC IV bags space
- In April 2023, Fresenius Kabi AG finalized the acquisition of JW Life Science, a Korea-based manufacturer of non‑PVC IV bags, for USD 70 million. This acquisition strengthens Fresenius Kabi’s position in the fast-growing Asian market
- In August 2022, ICU Medical Inc. solidified its commitment to providing safer alternatives by partnering with Grifols to offer non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection in the U.S. This expansion of their product line, ranging from 50 mL to 1000 mL, reflects the industry's focus on addressing concerns about patient safety and regulatory compliance with regards to intravenous therapy
- In April 2022, Fresenius Kabi responded to the growing demand for non-PVC IV bags by introducing Calcium Gluconate Injection in freeflex bags in the U.S. This launch underscores the industry's recognition of the benefits of non-PVC materials in enhancing patient care and reflects Fresenius Kabi's commitment to offering innovative solutions to healthcare providers
- In January 2022, ICU Medical Inc.'s acquisition of Smiths Medical further bolstered its position in the market for non-PVC IV bags. With Smiths Medical's portfolio encompassing syringe and ambulatory infusion devices, vascular access, and vital care, ICU Medical expands its offerings to provide comprehensive solutions that prioritize patient safety and address the evolving needs of healthcare facilities
